Essa Pharma Inc · Q2 2025 earnings

Briefing

ESSA Pharma reported a net loss of $6.37 million for the three months ended March 31, 2025, with total assets of $115.42 million and a decrease in operating expenses compared to the previous year.

ESSA Pharma Inc. reported a net loss of $6,374,787 for the three months ended March 31, 2025. The company's total operating expenses decreased to $7,381,677 from $10,493,489 in the same period last year, primarily due to the wind-down of clinical trials and cessation of preclinical work. Cash and cash equivalents stood at $86,308,345, and total assets were $115,415,420.

• Net loss for the three months ended March 31, 2025, was $6,374,787, an improvement from $8,989,535 in the prior year.
• Total operating expenses decreased significantly to $7,381,677 for the current quarter, down from $10,493,489 in the same period last year, reflecting the termination of clinical trials.
• Cash and cash equivalents as of March 31, 2025, were $86,308,345, indicating a strong liquidity position despite ongoing losses.
• The company's strategic shift to wind down clinical and preclinical development programs is reflected in reduced research and development expenditures.

Headline financials

Revenue & EPS history

ESSA Pharma Inc. is currently undergoing a comprehensive review of its strategic options to maximize shareholder value, following the termination of its clinical trials. The company anticipates continued losses as it winds down its development programs and evaluates future product candidates.